NurExone Biologic Overview
Nurexone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons. The company is developing a revolutionary biological extracellular vesicles-based technology drug platform to treat damage in the Central Nerve System (CNS). NurExone’s novel approach to SCI treatment is based on the perspective that intranasal exosome administration has broad potential and offers an alternative to other treatments that are under development to treat SCI. Extensive research, conducted at Prof. Shulamit Levenberg’s lab at the Technion, Haifa in collaboration with Prof. Danny Offen from Tel Aviv University tested a novel proprietary treatment using intranasal administration of Exosomes derived from mesenchymal stem cells. Their exosomes were loaded with PTEN siRNA to target complete spinal cord lesion in rats. The research showed significant functional recovery.
Cumulative Funding Raised Over Time ($)
$838KJan 2025
$2.8MSep 2024
Latest News
growth-positive
CEO Chat with Dr. Lior Shaltiel, CEO of NurExone Biologic Inc.
NurExone, an Israeli startup now based in Canada, is making strides in the field of biotechnology with its innovative exosome-based treatments for spinal cord injuries and other nerve damage. The company, which originated from research at the University of Tel Aviv and the Technion, has developed a platform technology with multiple indications, including ExoPTEN for acute spinal cord injury. NurExone has received orphan drug designation in both Europe and the United States. The company is publicly traded and is planning to uplist to the US market, indicating a growth-positive trajectory. Their exosome technology is seen as a breakthrough in drug delivery, reducing inflammation and promoting regeneration in damaged tissues.
Product StagePublic Trading
growth-positive
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
NurExone Biologic Inc, a biopharmaceutical company, is gaining recognition for its leadership in developing exosome-based regenerative therapies. Dr. Ina Sarel, the Director of Clinical and Regulatory Affairs, will speak at the Precision EV Forum 2025, highlighting the companys progress in regulatory and clinical development. NurExones lead program, ExoPTEN, targets central nervous system repair and has received Orphan Drug Designation for acute spinal cord injury. The company is actively engaging with the FDA to advance its innovative therapies. The forum will feature global leaders in exosome therapeutics, emphasizing the growing interest in NurExones work.
growth-positive
NRXBF Treatment Restores Sight
NurExone is developing ExoPTEN, a treatment for acute spinal cord injuries, and is conducting preclinical tests for other conditions like glaucoma. Recent preclinical results show promising outcomes, with higher doses of ExoPTEN leading to improved visual signal strength in optic nerve injury models and regained motor function in spinal cord injury models. These findings demonstrate a dose-dependent therapeutic effect and move ExoPTEN closer to human trials. The company also reported improved financial results, maintaining a strong cash position and low liabilities. These developments highlight NurExones potential for growth and innovation in medical treatments.
Product Stage
growth-positive
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model
NurExone Biologic Inc, a biopharmaceutical company, announced promising preclinical results for its lead candidate, ExoPTEN, in treating glaucoma. Conducted in collaboration with the Goldschleger Eye Institute, the study demonstrated a dose-dependent therapeutic effect in an eye model of glaucoma, showing reproducible and measurable recovery of visual function. These findings validate ExoPTENs potential as a regenerative therapy for optic nerve damage. The study marks a significant step towards future clinical trials, highlighting the effectiveness of NurExones exosome-based platform in delivering siRNA cargo to protect and regenerate neural tissue.
Product Stage
growth-positive
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
NurExone Biologic Inc, a biopharmaceutical company specializing in exosome-based regenerative therapies, has announced plans to establish its first U.S. commercial exosome production facility in Indianapolis, Indiana. This expansion is supported by an incentive offer of up to $255,000 from the Indiana Office of Commerce. The new facility will serve as Exo-Tops U.S. manufacturing base, producing exosomes for both NurExones therapeutic pipeline and business-to-business opportunities in regenerative aesthetics. The move aims to strengthen NurExones U.S. supply chain and contribute to Indianas biomanufacturing growth. The company is also progressing towards first-in-human clinical trials of ExoPTEN and plans to uplist to a major U.S. stock exchange.
Expand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2.84M |
| Last funding | $838K |
| Stage | Public |
| Rounds | 3 |
| Investors | 1 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | nurexone.com/ |
Locations
Haifa, Israel
Photos & Videos
1 item(s)
NurExone Biologic Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsTags (5)
neurosciencecns-disordersnon-invasivepharmaceuticalsdrug-discoveryNurExone Biologic Financials
$2.84M
Total funding
Undisclosed
Capital raised
$838K
Last funding
Public
Funding stage
3
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$838KJan 2025
$2.8MSep 2024
Private Equity Funding
PIPE
Jan 2025
$838K
PIPE
Sep 2024
$2M
Undisclosed Investor(s)
Public Offering / Exit
POEvent
Jul 2022
Undisclosed
NurExone Biologic Lifecycle
Cumulative Funding Raised Over Time
$838KJan 2025
$2.8MSep 2024
All Events
PIPE
Jan 2025
$838K
PIPE
Sep 2024
$2M
Undisclosed Investor(s)
POEvent
Jul 2022
Undisclosed
NurExone Biologic News
120 articles
growth-positive
CEO Chat with Dr. Lior Shaltiel, CEO of NurExone Biologic Inc.
NurExone, an Israeli startup now based in Canada, is making strides in the field of biotechnology with its innovative exosome-based treatments for spinal cord injuries and other nerve damage. The company, which originated from research at the University of Tel Aviv and the Technion, has developed a platform technology with multiple indications, including ExoPTEN for acute spinal cord injury. NurExone has received orphan drug designation in both Europe and the United States. The company is publicly traded and is planning to uplist to the US market, indicating a growth-positive trajectory. Their exosome technology is seen as a breakthrough in drug delivery, reducing inflammation and promoting regeneration in damaged tissues.
Product StagePublic Trading
growth-positive
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
NurExone Biologic Inc, a biopharmaceutical company, is gaining recognition for its leadership in developing exosome-based regenerative therapies. Dr. Ina Sarel, the Director of Clinical and Regulatory Affairs, will speak at the Precision EV Forum 2025, highlighting the companys progress in regulatory and clinical development. NurExones lead program, ExoPTEN, targets central nervous system repair and has received Orphan Drug Designation for acute spinal cord injury. The company is actively engaging with the FDA to advance its innovative therapies. The forum will feature global leaders in exosome therapeutics, emphasizing the growing interest in NurExones work.
growth-positive
NRXBF Treatment Restores Sight
NurExone is developing ExoPTEN, a treatment for acute spinal cord injuries, and is conducting preclinical tests for other conditions like glaucoma. Recent preclinical results show promising outcomes, with higher doses of ExoPTEN leading to improved visual signal strength in optic nerve injury models and regained motor function in spinal cord injury models. These findings demonstrate a dose-dependent therapeutic effect and move ExoPTEN closer to human trials. The company also reported improved financial results, maintaining a strong cash position and low liabilities. These developments highlight NurExones potential for growth and innovation in medical treatments.
Product Stage
growth-positive
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model
NurExone Biologic Inc, a biopharmaceutical company, announced promising preclinical results for its lead candidate, ExoPTEN, in treating glaucoma. Conducted in collaboration with the Goldschleger Eye Institute, the study demonstrated a dose-dependent therapeutic effect in an eye model of glaucoma, showing reproducible and measurable recovery of visual function. These findings validate ExoPTENs potential as a regenerative therapy for optic nerve damage. The study marks a significant step towards future clinical trials, highlighting the effectiveness of NurExones exosome-based platform in delivering siRNA cargo to protect and regenerate neural tissue.
Product Stage
growth-positive
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
NurExone Biologic Inc, a biopharmaceutical company specializing in exosome-based regenerative therapies, has announced plans to establish its first U.S. commercial exosome production facility in Indianapolis, Indiana. This expansion is supported by an incentive offer of up to $255,000 from the Indiana Office of Commerce. The new facility will serve as Exo-Tops U.S. manufacturing base, producing exosomes for both NurExones therapeutic pipeline and business-to-business opportunities in regenerative aesthetics. The move aims to strengthen NurExones U.S. supply chain and contribute to Indianas biomanufacturing growth. The company is also progressing towards first-in-human clinical trials of ExoPTEN and plans to uplist to a major U.S. stock exchange.
Expand
growth-positive
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
NurExone Biologic Inc, a biopharmaceutical company, announced significant corporate updates, including the grant of a patent by the Israel Patent Office for the production of extracellular vesicles from stem cells. This strengthens their international IP portfolio. The company is actively participating in U.S. conferences to showcase its ExoTherapy technology and engage with potential partners and investors. Additionally, NurExone closed a non-brokered private placement, raising C$632,655.68 to support its preclinical pipeline and U.S. manufacturing initiatives. This financing positions the company to accelerate its growth strategy.
InvestmentProduct Stage
growth-positive
NRXBF Gets Patent for Exciting Cell Technology
NurExone is developing ExoPTEN, a treatment for acute spinal cord injuries, currently in the preclinical stage. The company has shown promising results in preclinical tests, indicating potential benefits for thousands of patients. Recent independent tests revealed that NurExones exosomes outperform industry standards in key healing tasks. The company was awarded a US patent for its exosome production process, enhancing its intellectual property protection. Financial results show an improved cash position and effective expense management. The CEO of the US subsidiary highlighted the potential for ExoPTEN in regenerative medicine, with plans to scale production in the US. A preclinical study demonstrated significant motor function recovery in animals treated with ExoPTEN, suggesting its potential as a breakthrough treatment.
Product StageInvestmentPartners
growth-positive
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
NurExone Biologic Inc., a biopharmaceutical company focused on exosome-based regenerative therapies, has received a Notice of Allowance from the United States Patent and Trademark Office for its proprietary exosome production process. This patent strengthens NurExones global market position by securing long-term protection for its manufacturing process. The company has also acquired a GMP-grade Master Cell Bank, reinforcing its supply chain. These developments pave the way for NurExones first-in-human trials and future commercial positioning. The patented process is licensed exclusively from the Technion Research and Development Foundation, Ltd. NurExones lead product, ExoPTEN, shows promise in treating central nervous system injuries, with plans for clinical trials in the U.S. and Europe.
Product StageAcquisition
growth-positive
NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results
NurExone Biologic Inc, a preclinical-stage biotechnology company, announced its financial results for Q2 2025 and provided updates on its activities. The company raised C$2.3 million through a private placement in April 2025, which will be used for working capital and clinical development. NurExone plans to initiate a Phase 1/2a trial for ExoPTEN in 2026, pending regulatory approval. The company has validated its manufacturing process for exosome production and plans to transfer this technology to its U.S. subsidiary, Exo-Top Inc. NurExone was also accepted into the ARMI HealthTech Hub Accelerator to support its U.S. growth and manufacturing strategy.
InvestmentProduct Stage
growth-positive
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
NurExone Biologic Inc. has successfully closed a C$0.78 million private placement. The company announced promising preclinical imaging results for its ExoPTEN treatment, which shows potential in repairing spinal cord injuries. The imaging analysis demonstrated improved structural integrity and organization in treated animals compared to controls. NurExone is preparing for its first-in-human clinical trial of ExoPTEN, pending regulatory approval. The advanced MRI-DTI technique used in the study provided detailed insights into the microstructural integrity of the spinal cord, supporting ExoPTENs neuroprotective and regenerative capabilities.
InvestmentProduct Stage
growth-positive
NRXBF Treatment Shows Remarkable Treatment Properties
NurExone is developing ExoPTEN, a product aimed at treating acute spinal cord injuries, and has reported promising preclinical results. The company released independent test results showing its exosomes outperforming industry standards, suggesting potential applications in various medical fields. The CEO highlighted the regenerative capabilities of their exosomes and plans to scale production in the U.S. with a patent-pending process. A preclinical study demonstrated significant recovery in motor function in animals treated with ExoPTEN. NurExone plans to initiate a Phase 1/2a clinical trial for ExoPTEN in 2026, marking a significant advancement for the company.
Product StagePartners
growth-positive
NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard
NurExone Biologic Inc. announced that an independent study demonstrated their exosomes outperform a commercial industry standard in nerve repair and wound healing. The exosomes, produced by their U.S. subsidiary ExoTOP Inc., show promise in therapeutic and aesthetic markets, offering potential applications in skin rejuvenation, wound care, and orthopedic tissue repair. The study, conducted by TAmiRNA, revealed that NurExones exosomes are enriched with microRNAs that support key healing tasks, exhibiting higher neurological potential and anti-inflammatory activity. This positions NurExones exosomes as a versatile platform for therapeutic nerve repair and aesthetic applications.
Product StagePartners
growth-positive
NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
NurExone Biologic Inc. has been named a finalist in the Falling Walls Venture 2025, a prestigious competition for science-based start-ups. The company, which focuses on regenerative exosome-based therapies for central nervous system injuries, will present its platform at the Falling Walls Science Summit in Berlin. This recognition provides NurExone with opportunities to connect with investors, clinicians, and industry partners. Their lead product, ExoPTEN, has shown promising preclinical results and aims to address significant markets in spinal cord and optic nerve injury. The company is also working towards clinical trials in the U.S. and Europe, supported by regulatory milestones like the Orphan Drug Designation.
Product StagePartners
growth-positive
NRXBF Treatment Restores Mobility to Spinal Injury Patients
NurExone is developing ExoPTEN, a treatment for acute spinal cord injuries, and has announced promising preclinical results. The study showed that higher doses of ExoPTEN led to regained motor function in animals with spinal cord injuries. The company plans to initiate a Phase 1/2a clinical trial in 2026. Additionally, ExoPTEN has shown potential in treating optic nerve damage, with significant recovery observed in preclinical studies. The company collaborates with the Goldschleger Eye Institute, where encouraging results were reported. These developments are seen as positive steps forward for NurExone.
Product StagePartners
growth-positive
New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model
NurExone Biologic Inc announced promising preclinical results for its ExoPTEN treatment, showing that 100% of small animals treated with a higher dose regained motor function after spinal cord injury. The study demonstrated a dose-dependent improvement in gait recovery, with significant enhancements in balance, strength, and coordination. The high dose was well tolerated, with no side effects observed. The company plans to conduct further studies to explore alternative dosing regimens and optimize ExoPTENs manufacturing processes. These efforts aim to refine the drugs therapeutic profile and engage with regulatory authorities.
Product Stage
growth-positive
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
NurExone Biologic Inc, a biotech company specializing in exosome-based therapies for central nervous system injuries, has been accepted into the HealthTech Hub (HTH) Accelerator Program. This acceptance will aid the companys expansion into the U.S. market, facilitated by its U.S. subsidiary, Exo-top Inc., which focuses on GMP-compliant exosome manufacturing. The HTH program, supported by ARMI and Mass General Brigham, provides strategic guidance to innovative companies, enhancing their U.S. clinical relevance and commercialization strategies. Additionally, NurExones shareholders approved an amended omnibus incentive plan, allowing for flexible equity incentive awards. This development is expected to bolster NurExones visibility in the U.S. regenerative medicine ecosystem.
PartnersExpand
growth-positive
NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation
NurExone Biologic Inc announced promising new manufacturing process data at the ISEVR conference, showcasing the viability and potency of cells from its Master Cell Bank (MCB). This development is crucial for the GMP-compliant manufacturing of exosomes for its lead therapeutic candidate, ExoPTEN, and its subsidiary, Exo-Top Inc. The company is also seeking shareholder approval for its amended omnibus incentive plan at its upcoming meeting. The advancements in manufacturing processes demonstrate consistent exosome yields and preserved biological potency, which are vital for supporting clinical trials and future commercial supply. This progress marks a significant step toward delivering impactful therapies for traumatic nerve injuries.
Product Stage
growth-positive
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
NurExone Biologic Inc announced its plans to initiate a Phase 1/2a clinical trial in 2026 for ExoPTEN, an exosome-based therapy for acute spinal cord injuries. The announcement was made at the annual meeting of the American Spinal Injury Association, where Professor Nahshon Knoller presented the companys future clinical trial plans and preclinical study results. The trial will enroll adult patients with traumatic spinal cord injuries and will consist of a dose-escalation study followed by a randomized, double-blind, placebo-controlled trial. This marks a significant milestone for NurExone as it transitions from preclinical to clinical stages, highlighting the potential of ExoPTEN to address unmet needs in spinal cord injury treatment.
Product Stage
growth-positive
NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
NurExone Biologic Inc, a preclinical-stage biotechnology company, announced its financial results for Q1 2025, highlighting significant achievements. The company was included in the 2025 TSX Venture 50™ list, showcasing its strong market performance with a 110% share price appreciation and a 209% increase in market cap. NurExone formed a U.S. subsidiary, Exo-Top Inc., to focus on exosome production and commercialization, appointing Jacob Licht as CEO. The company raised approximately C$480 thousand through a private placement and C$866 thousand through warrant exercises. These developments reflect NurExones strategic advances in exosome-based therapies for central nervous system injuries.
InvestmentManagement ChangesExpand
growth-positive
NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
NurExone Biologic Inc, a preclinical-stage biotechnology company, presented promising data on its exosome-based therapy, ExoPTEN, for optic nerve regeneration at the ARVO conference. The study demonstrated restored retinal activity and improved optic nerve structure in a rat model, generating significant interest from the scientific community. The company is expanding its research to include glaucoma models, aiming to address vision incapacitation. ExoPTEN is part of NurExones ExoTherapy platform, which also targets spinal cord and facial nerve regeneration. The therapy has shown potential in restoring motor function in preclinical spinal cord studies, indicating a scalable approach to nervous system repair.
Product Stage
growth-positive
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
NurExone Biologic Inc, a preclinical-stage biotechnology company, is enhancing its presence in the European financial and healthcare sectors by participating in key events such as INVEST 2025 in Stuttgart, the Healthtech Roadshow in Zurich, and BioProcess International Europe in Hamburg. The company is focusing on exosome-based therapies for central nervous system injuries and has identified a third potential therapeutic indication for its lead drug, ExoPTEN. These activities aim to strengthen NurExones relationships with investors and partners, particularly in German-speaking markets, and to increase visibility for its innovative regenerative medicine approaches.
Product StagePartners
growth-positive
NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
NurExone Biologic Inc, a preclinical-stage biotechnology company, is pioneering exosome-based therapies for central nervous system injuries. The company presented new data at the 2025 International Society for Extracellular Vesicles Annual Meeting, showcasing its lead candidate, ExoPTEN, which promotes significant functional recovery and regeneration in facial nerve injuries. This marks the companys third therapeutic indication, alongside spinal cord injury and optic nerve regeneration. The study, conducted in collaboration with the Levenberg lab at the Israel Institute of Technology, opens a new potential therapeutic avenue for peripheral nerve injury conditions. The company is preparing to submit an Investigational New Drug application for ExoPTEN in acute spinal cord injury.
Product Stage
growth-positive
NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario
NurExone Biologic Inc., a preclinical-stage biotechnology company, has appointed Jacob Licht as CEO of its subsidiary Exo-Top Inc. and VP of Corporate Development at NurExone. Exo-Top, based in the U.S., will be crucial for the companys exosome manufacturing and commercialization strategy. Lichts role will focus on establishing manufacturing capabilities, strategic partnerships, and corporate initiatives to prepare for clinical trials and future fundraising. His extensive experience in biotech operations and strategic deals aligns with NurExones growth strategy. Additionally, NurExone has completed its continuance from Alberta to Ontario, as approved by shareholders.
Management Changes
growth-positive
NRXBF Enters Crucial Stage in Good Shape
NurExone is advancing its development of ExoPTEN, a treatment for acute spinal cord injuries, with promising preclinical results showing motor function recovery and improved blood flow. The company plans to submit an IND to the FDA in the second half of 2025. Financially, NurExone has raised $1.6 million through a non-brokered private placement to support its testing process. The company is also working on uplisting its stock in the US to attract more investors and has been recognized in the 2025 TSX Venture 50 for its strong market performance. Additionally, NurExone is establishing a US-based subsidiary, Exo-Top Inc., to support its future nanodrug pipeline.
Product StageInvestmentPublic Trading
growth-positive
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
NurExone Biologic Inc. reported significant progress in Q4 2024, focusing on advancing its ExoPTEN therapy for spinal cord injuries. The company is preparing to submit an IND application to the FDA, marking a critical step towards clinical trials. Additionally, NurExone reinforced its supply chain by acquiring a master cell bank and expanded its R&D capabilities with new facilities. Financially, the company strengthened its position by raising approximately C$0.24 million through a private placement and warrant exercises. These developments highlight NurExones commitment to advancing its therapeutic pipeline and enhancing its operational infrastructure.
Product StageInvestment
growth-positive
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
NurExone Biologic Inc. has successfully closed a non-brokered private placement, raising C$2,303,105. The funds will be used for working capital, establishing a U.S. production facility, and pursuing an uplisting to a major U.S. exchange. The companys lead product, ExoPTEN, has shown promising preclinical results for treating central nervous system injuries. The investment marks a significant milestone, supporting NurExones strategic initiatives and expanding its operational footprint. The company is focused on developing regenerative exosome-based therapies and aims to enhance its presence in key markets.
InvestmentExpand
growth-positive
NRXBF Test Results Bolster Prospects
NurExone is developing ExoPTEN, a treatment for acute spinal cord injuries, and has announced promising preclinical results demonstrating motor function recovery and improved blood flow. These findings are expected to support an upcoming IND submission to the FDA. The company has been recognized in the 2025 TSX Venture 50 for its strong market performance, including a 110% share price increase and 209% market cap growth. NurExone is expanding its presence in the U.S. by forming a subsidiary, Exo-Top Inc., to support its future nanodrug pipeline. Additionally, the company will present at the ISCT 2025 Annual Meeting, showcasing its potential breakthrough treatments.
Product StageExpand
growth-positive
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
NurExone Biologic Inc. has successfully completed a preclinical study for its ExoPTEN treatment, which is crucial for its Investigational New Drug (IND) submission. The study demonstrated significant improvements in motor function recovery and blood flow at the site of spinal cord injury, indicating ExoPTENs potential as a transformative therapeutic candidate. The company is focused on developing regenerative exosome-based therapies for central nervous system injuries and is preparing for first-in-human trials. NurExone has also established a U.S. subsidiary, Exo-Top Inc., to support its North American growth strategy.
Product Stage
growth-positive
NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
NurExone Biologic Inc. has been recognized as part of the 2025 TSX Venture 50™, highlighting its strong market performance and leadership in exosome-based therapies for central nervous system injuries. The company achieved a 110% share price appreciation and 209% market cap growth, reflecting significant investor confidence. Key milestones include progress in developing ExoPTEN, a proprietary exosome therapy for spinal cord injuries, and establishing a U.S. subsidiary to enhance exosome production. This recognition underscores NurExones commitment to advancing regenerative medicine and its strategic advances in the past year.
growth-positive
NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award
NurExone Biologic Inc. announced its participation in the MIXiii 2025 Health Tech conference in Israel, where it will present preclinical results on optic nerve regeneration, a promising treatment for glaucoma and other eye diseases. The company is advancing its research with a new preclinical study on its lead product, ExoPTEN, aiming to expand on positive results from previous studies. Professor Michael Belkin, a key scientific advisor and collaborator, will be honored with a Lifetime Achievement Award at the conference. His Belkin Vision technology was recently acquired by Alcon for up to $466 million. The event highlights NurExones innovative work in regenerative medicine and its potential impact on treating neurodegenerative eye diseases.
Product Stage
growth-positive
NRXBF Pushing into US Market
NurExone, trading under OTC:NRXBF, is developing ExoPTEN, a treatment for acute spinal cord injuries, and is conducting preclinical tests for other conditions. The company has been recognized in the 2025 TSX Venture 50, highlighting its strong market performance with a 110% share price appreciation and 209% market cap growth. NurExone is expanding its presence in the U.S. by forming a subsidiary, Exo-Top Inc., to support its nanodrug pipeline. The company will present at the ISCT 2025 Annual Meeting, showcasing significant findings in optic nerve damage repair. Collaborating with the Goldschleger Eye Institute, NurExones study shows promising results for ExoPTEN in treating conditions like glaucoma.
Product StageExpandPartners
growth-positive
NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock
NurExone Biologic Inc. has been recognized as one of the top-performing companies in the 2025 TSX Venture 50™, highlighting its leadership in exosome-based therapies and regenerative medicine for central nervous system injuries. The company experienced a 110% share price appreciation and 209% market cap growth, reflecting strong investor confidence. Key milestones include progress in developing ExoPTEN, a proprietary exosome therapy for spinal cord injuries, and establishing a U.S. subsidiary to enhance exosome production capabilities. This recognition underscores NurExones commitment to advancing its clinical pipeline and expanding its presence in the U.S.
Product StageExpand
growth-positive
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
NurExone Biologic Inc, a biotech company listed on TSXV, OTCQB, and Frankfurt, is set to present its innovative ExoPTEN therapy at the ISCT 2025 Annual Meeting in New Orleans. The presentation will highlight preclinical data showing significant improvements in motor and sensory functions in small animal models of spinal cord injury. This participation is part of NurExones strategy to expand its presence in the U.S. market. The company has recently launched a U.S. subsidiary, Exo-Top Inc., to produce GMP exosomes for research and therapeutic use. NurExone aims to increase its visibility and shareholder value by showcasing its advances at prestigious events and pursuing U.S. listing opportunities.
Product StageExpand
growth-positive
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
NurExone Biologic Inc. has announced the formation of a U.S.-based subsidiary, Exo-Top Inc., to advance GMP-grade exosome production. This move follows the acquisition of a Master Cell Bank of Mesenchymal Stem Cells, providing a unique and sustainable source for exosome production. Exo-Top aims to supply high-quality exosomes for NurExones drug development and other pharmaceutical companies, creating new revenue streams. The company plans to pursue an uplisting to a major U.S. exchange to strengthen its market position. This strategic expansion enhances NurExones control over its production process and supports its growth strategy.
AcquisitionExpand
growth-positive
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
NurExone Biologic Inc, a company focused on exosome-based therapies for regenerative medicine, announced the closing of a non-brokered private placement, raising C$479,917.76 through the sale of 856,996 units at C$0.56 per unit. Additionally, the company received C$727,755.04 from the exercise of 2,140,456 Class A Warrants at C$0.34 each, issued during a previous offering in August 2023. The funds will be used for working capital. Each unit includes one common share and one warrant, with the latter allowing the purchase of an additional share at C$0.70 for 36 months, subject to acceleration conditions. The offering is pending TSX Venture Exchange approval and is subject to a statutory hold period.
Investment
growth-positive
NurExone Biologic Secures Master Cell Bank
NurExone Biologic Inc, a developer of exosome-based therapies, has acquired a master cell bank from a U.S. manufacturer. This acquisition is a significant step in ensuring a stable and scalable supply chain for exosome-based therapies, which are crucial for regenerative medicine. The master cell bank provides a GMP-grade source of human bone marrow mesenchymal stem cells, essential for producing exosomes. This acquisition allows NurExone to advance its therapies without incurring product royalty fees or annual licensing fees. The acquisition comes at a strategic time, as the FDA has recently approved the first-ever Mesenchymal Stromal Cell-based therapy, highlighting the potential of these therapies in regenerative medicine.
Acquisition
growth-positive
NRXBF Announces Important Test Results
NurExone is advancing its ExoPTEN product, aimed at treating acute spinal cord injuries and other conditions. Recent preclinical tests showed promising results in repairing optic nerve damage, potentially benefiting thousands of patients. The study demonstrated significant recovery in signal transmission and survival of retinal ganglion cells. The company collaborates with the Goldschleger Eye Institute, whose lead investigator expressed optimism about ExoPTENs potential. With a market size of $5.5 billion and a growth rate of over 8% annually, the treatment holds substantial promise. ExoPTEN has also received the Orphan Medicinal Product Designation from the European Medicines Agency, offering incentives like market exclusivity and financial support, which could streamline regulatory processes and reduce costs.
growth-positive
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
NurExone Biologic Inc., a biopharmaceutical company, announced promising results from an expanded preclinical study of its drug ExoPTEN, aimed at repairing optic nerve damage. Conducted in collaboration with the Goldschleger Eye Institute at Sheba Medical Center, the study demonstrated significant recovery in retinal activity and survival of retinal ganglion cells in treated eyes. These findings suggest ExoPTENs potential as a treatment for glaucoma and optic nerve trauma, with plans to advance to a larger study. The optic nerve disorders treatment market is expected to grow significantly, indicating a positive outlook for NurExones innovative therapy.
Partners
growth-positive
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
EmergingGrowth.com announced the schedule for its 77th Emerging Growth Conference, set to take place on December 4 and 5, 2024. The conference will feature a range of companies from various growth sectors, highlighting their management teams, innovative products, and strategies for long-term growth. Keynote speakers from companies such as ATRenew Inc., Beneficient, U.S. Energy Corporation, and others will present during the event. The conference aims to provide insights into companies with strong growth potential and offers an opportunity for attendees to engage with industry leaders. The event is positioned as a platform for showcasing emerging companies and their potential for future success.
growth-positive
NRXBF: Promising Company Releases Results
NurExone is developing ExoPTEN, a treatment for acute spinal cord injuries, targeting a market of approximately 50,000 new cases globally per year. The company has received the Orphan Medicinal Product Designation from the European Medicines Agency (EMA), which offers incentives like market exclusivity, grants, and tax credits. This follows the Orphan Drug Designation from the FDA in the United States in 2023. The designations highlight the potential seen by government agencies in NurExones treatment. The companys financial results for 3Q2024 show reduced expenses, demonstrating fiscal discipline. Research began at the University level, and NurExone holds an exclusive worldwide license from Technion and Tel Aviv University, along with five patent families.
growth-positive
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
NurExone Biologic Inc, a biopharmaceutical company, reported its financial and operational results for the third quarter of 2024. The company raised significant funds through private placements, generating gross proceeds of C$1,610,147.55 in September and C$127,499.90 in November. NurExone also engaged Allele Capital Partners for investor relations and Independent Trading Group and Oak Hill Financial Inc. for market-making and advisory services. The European Medicines Agency granted Orphan Medicinal Product Designation for NurExones ExoPTEN therapy, a significant milestone for treating acute spinal cord injury in Europe. Despite a net loss of US$1.25 million in Q3 2024, the company saw increased research and development expenses and finance income compared to the previous year.
InvestmentPartners
growth-positive
NRXBF Gains Another Governmental Designation
NurExone, a company developing ExoPTEN for acute spinal cord injuries, has received the Orphan Medicinal Product Designation from the European Medicines Agency (EMA). This designation offers incentives such as ten years of market exclusivity, access to grants, and reduced-cost scientific advice. The company had previously received the Orphan Drug Designation from the FDA in the United States, which provides similar benefits. The designations highlight the potential seen by government agencies in NurExones treatment. The research, which began at the University level, has shown promising results in preclinical studies, demonstrating significant functional recovery in animal models. NurExone holds an exclusive worldwide license from Technion and Tel Aviv University and has developed its own intellectual property with five families of patents.
growth-positive
NurExone Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury
NurExone has secured the European Medicines Agency (EMA) Orphan Status for its ExoPTEN treatment, which is aimed at spinal cord injury. This designation is significant as it can provide various benefits, including market exclusivity, reduced fees, and assistance in the drug development process. The recognition from EMA is likely to enhance NurExones position in the market and potentially attract further investment or partnerships. The article does not mention any specific financial details, partnerships, or customer acquisitions related to this development.
growth-positive
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
NurExone Biologic Inc, a biopharmaceutical company, announced that its ExoPTEN therapy has received Orphan Medicinal Product Designation from the European Medicines Agency (EMA). This designation is a significant milestone for NurExone, as it facilitates faster market entry into Europe for its exosome-based regenerative therapy aimed at treating acute spinal cord injuries. The designation provides incentives such as 10 years of market exclusivity, access to grants, and potential tax credits, which can reduce development costs and streamline regulatory processes. This recognition by the EMA, along with a similar designation from the US FDA, positions NurExone to address the unmet needs of spinal cord injury patients globally.
growth-positive
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
NurExone Biologic Inc., a biopharmaceutical company, announced the closing of the final tranche of its non-brokered private placement, raising a total of $1,737,647.45. This funding will support asset development, working capital, and general corporate purposes. The offering included the issuance of 3,159,359 Units, each comprising one Common Share and one Warrant. The Warrants allow the purchase of an additional Common Share at $0.70, with potential acceleration of the expiry date. James A. Richardson, a director of the company, participated in the offering, which was considered a related party transaction. The proceeds are intended to advance the companys position in the regenerative medicine market.
Investment
growth-positive
NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule
NRx Pharmaceuticals is set to present at the Emerging Growth Conference on October 31, 2024, highlighting its strategic move towards acquiring a national network of interventional psychiatry clinics through its HOPE Therapeutics subsidiary. The clinics focus on treating suicidal depression and PTSD using innovative therapies such as ketamine and transcranial magnetic stimulation. This move is part of NRx Pharmaceuticals broader strategy to expand its footprint in the mental health sector, leveraging advanced therapeutic approaches. The presentation is expected to attract significant investor interest, given the companys focus on growth sectors and innovative management. The event underscores NRx Pharmaceuticals commitment to expanding its therapeutic offerings and enhancing its market position.
Acquisition
growth-positive
Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now
EmergingGrowth.com announced the schedule for its 76th Emerging Growth Conference, taking place on October 30 and 31, 2024. The conference aims to highlight companies across various growth sectors that demonstrate strong management, innovative products, and potential for long-term growth. The event features keynote speakers from multiple companies, including Monumental Energy Corp., Vox Royalty Corp., and Bioxytran, Inc., among others. The conference provides a platform for these companies to present their strategies and innovations to potential investors and partners. The event is sponsored by QuoteMedia, which offers dynamic investor relations solutions.
growth-positive
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
EmergingGrowth.com, a prominent small cap media portal, has announced the schedule for its 76th Emerging Growth Conference, set to take place on October 30 and 31, 2024. The conference aims to spotlight companies across various growth sectors, highlighting those with strong management, innovative products, and long-term growth potential. The event will feature keynote speakers from several companies, including Viomi Technology Co., Ltd., BioVaxys Technology Corp., ASP Isotopes Inc., and others. The conference provides a platform for these companies to present their strategies and innovations to potential investors and partners. The event is sponsored by QuoteMedia, which offers dynamic investor relations solutions.
growth-positive
NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA
NurExone Biologic Inc., a biopharmaceutical company specializing in exosome-based therapies, announced its participation in two major conferences in the United States this November. These events, the American Academy for Extracellular Vesicles Conference and the ISEV TECH Conference, highlight NurExones growing influence in the field of regenerative medicine. The company aims to showcase its innovative treatments for spinal cord injuries and optic nerve damage, leveraging exosome technology. The conferences provide a platform for NurExone to engage with leading researchers and industry innovators, potentially paving the way for strategic partnerships and expansion into the U.S. market. NurExones ExoPTEN product, which has shown promising results in preclinical studies, has been granted Orphan Drug Designation by the FDA.
growth-positive
Initiating Coverage of NRXBF
NurExone, a clinical-stage biotech company, is developing ExoPTEN, a novel treatment for spinal cord injuries using exosome-based technology. The company has shown promising preclinical results, demonstrating significant functional recovery in animal models. NurExone holds an exclusive worldwide license from Technion and Tel Aviv University to develop and commercialize this technology, and has developed its own intellectual property with five patent families. The company received Orphan Drug Designation for ExoPTEN in 2023, offering incentives such as tax credits and market exclusivity. This designation and the promising test results highlight the companys potential in treating central nervous system injuries and possibly licensing its technology to major pharmaceutical companies.
Partners
growth-positive
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
NurExone Biologic Inc., a biopharmaceutical company specializing in exosome-based therapies, announced a non-brokered private placement of up to 3,636,363 units at $0.55 per unit, aiming to raise up to $2,000,000. The first tranche of the offering has closed, raising $1,610,147.55. The funds will be used for working capital purposes. The offering reflects confidence from existing shareholders in the companys strategic direction and long-term growth potential. Each unit consists of one common share and one common share purchase warrant. The offering is subject to regulatory approvals and may constitute a related party transaction under MI 61-101.
Investment
growth-positive
NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
NurExone Biologic Inc., a biopharmaceutical company specializing in exosome-based therapies, announced its participation in several prestigious conferences in October 2024. These events include the World Orphan Drug Congress in Barcelona, the Precision EV Forum in Cambridge, and the Israeli Society of Gene and Cell Therapys meeting in Israel. The company aims to showcase its advancements in exosome therapy, particularly its ExoPTEN nanodrug for acute spinal cord injuries. CEO Dr. Lior Shaltiel will also present at the Bioprocess International Conference in Boston. These engagements are expected to enhance NurExones visibility and foster potential collaborations in the field of regenerative medicine.
Partners
growth-positive
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
NurExone Biologic Inc. announced promising preclinical study results for its ExoPTEN therapy, which targets spinal cord injuries. The study demonstrated that ExoPTEN can effectively accumulate at the injury site up to seven days post-injury, suggesting a broad therapeutic window. This could potentially expand the number of treatable patients and enhance recovery outcomes. The findings are expected to positively impact the design of upcoming phase I/II clinical trials and patient care strategies. The company aims to leverage these results to recruit more patients for clinical trials and broaden the market for its therapy.
CustomersExpand
growth-positive
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
NurExone Biologic Inc., a biopharmaceutical company, announced its financial and operational results for the first half of 2024. Key highlights include a partnership with Vivox Ltd. for preclinical testing of ExoPTEN, uplisting to the OTCQB Venture Market, and expansion of ExoPTENs patent coverage to Japan. The company also entered into a consulting agreement with Dr. Yona Geffen to support clinical activities. Financially, NurExone saw increased R&D and administrative expenses, resulting in a net loss of $1.33 million for Q2 2024. However, cash reserves improved significantly due to a private placement and warrant exercises. The company is preparing for clinical trials and commercial production, aiming for sustained growth.
PartnersPublic TradingExpandInvestment
growth-positive
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
NurExone Biologic Incs CEO, Dr. Lior Shaltiel, has been invited to speak at the Bioprocess International Conference in Boston, MA, and the Pioneering Israel Medicine Conference in New York, NY. These invitations highlight the companys leadership in regenerative medicine and exosome technology. Dr. Shaltiel will present the companys ExoPTEN nanodrug, a potential treatment for acute spinal cord injuries and other central nervous system indications. The companys participation in these events is expected to enhance its influence in the field of regenerative medicine and exosome technologies.
Expand
growth-positive
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
NurExone Biologic Inc. has announced significant advancements in their manufacturing process of exosomes, which are at the heart of the Company’s innovative ExoPTEN product being developed for the treatment of acute spinal cord injury and glaucoma. The company has demonstrated reliable production from multiple biological sources, providing flexibility in optimizing its exosome production method. The companys patented 3D culture is expected to facilitate commercial mass production of exosomes. The advancements are expected to pave the way to regenerative medicine treatments for a variety of clinical indications developed by NurExone independently as well as with future collaboration partners.
Investment
growth-positive
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
NurExone Biologic Inc. has announced new data for its ExoPTEN nanodrug, marking a significant step towards commercial-grade manufacturing. The study assessed the performance of ExoPTEN loaded with small interfering RNA (siRNA) produced by a new Good Manufacturing Practice (GMP) compliant Contract Research Organization (CRO) partner. The study focused on the capability of ExoPTEN to biologically target sites of inflammation and injury. The results showed exceptional homing capacity to the injured spinal cord, validating the quality of the siRNA produced by the GMP Partner and the use of NurExone’s exosomes as a drug delivery system.
Partners
growth-positive
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
NurExone Biologic Inc., a biopharmaceutical company, has announced the successful transfer of the manufacturing of the small interfering RNA (siRNA) sequence for its ExoPTEN nanodrug to a German producer with Good Manufacturing Practice (GMP) capabilities. The move is crucial for producing a drug for clinical trials and commercial sale. The siRNA from the new vendor achieved an approximately 80% reduction in expression of PTEN, demonstrating potency and effectiveness comparable to the siRNA from the companys previous, research-grade producer.
PartnersExpand
growth-positive
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
NurExone Biologic Inc. has received a Notice of Allowance for an ExoPTEN patent from the Israel Patent Office. The patent covers Extracellular Vesicles (EVs) comprising a phosphatase and tensin homolog (PTEN) inhibitor and their application use. The patent was originally submitted by the Technion Research and Development Foundation Ltd. and Ramot at Tel Aviv University Ltd. NurExone has also entered into a consulting agreement with Allele Capital Partners to provide investor relation services. The company will pay Allele Capital US$11,000 per month, which will increase to $14,500 upon the company uplisting to either the NYSE or NASDAQ.
InvestmentPartners
growth-positive
Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
NurExone Biologic Inc. has announced preliminary results from a small-scale controlled study exploring the use of its flagship nanodrug, ExoPTEN, for optic nerve recovery in a rat model at Sheba Medical Center. The study was initiated by Professor Michael Belkin, following the success of ExoPTEN in nerve regeneration in the spinal cord indication in preclinical models. The study showed promising results, with treated eyes exhibiting a peak similar to the healthy eye in the same animal indicating recovery of retinal response following optical nerve compression. The results suggest potential pathways for recovery of optic nerve function and overall healthy vision.
InvestmentExpand
Growth-Positive
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
EmergingGrowth.com, a leading independent small cap media portal, has announced the schedule for the 73rd Emerging Growth Conference on July 17 & 18, 2024. The conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. The conference will feature keynote speakers from various companies, including Immuron Limited, CytoMed Therapeutics, Ethema Health Corporation, NeuroBo Pharmaceuticals, and others.
Partners
growth-positive
Updates from NurExone: Growth Conference Presentation and Website Relaunch
NurExone Biologic Inc, a pioneering biopharmaceutical company, has announced two significant updates. The companys CEO, Dr. Lior Shaltiel, will be presenting at the Emerging Growth Conference – Biotech Feature, focusing on NurExones groundbreaking ExoTherapy platform and its nanodrug ExoPTEN under development for acute spinal cord injuries. In addition, NurExone has launched an updated website to improve communication and engagement with collaborators, pharmaceutical companies, and other stakeholders. The company is developing exosome-based therapies for central nervous system injuries.
Management ChangesExpand
growth-positive
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
NurExone Biologic Inc. has announced a pre-clinical study to explore the potential of its exosome-based therapies in regenerating damaged optic nerves. The study is led by Prof. Michael Belkin from Tel Aviv Universitys Goldschleger Eye Research Institute and Prof. Ygal Rotenstreich and Dr. Ifat Sher from the Sheba Medical Center Eye Institute. The global optic nerve disorders treatment market size was valued at US$3.4 billion in 2021, and is projected to reach US$5.3 billion by 2031. The study represents the next phase in NurExones strategy to expand the clinical indications for its exosome-loaded drugs.
InvestmentExpand
growth-positive
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
NurExone Biologic Inc, a pioneering biopharmaceutical company, has welcomed Dr. Yona Geffen as a consultant to support the companys preclinical and clinical activities. Dr. Geffen, who is currently the Vice President of Research and Development at Gamida Cell Ltd, brings over two decades of experience in leading clinical and drug development in the biotechnology and pharmaceutical industries. She will support the development of Chemistry, Manufacturing and Controls (CMC) for preclinical and clinical activities at NurExone, and will use her experience to help establish operations within Good Manufacturing Practices (GMP) production environments.
Management ChangesExpand
growth-positive
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
NurExone Biologic Inc., a biopharmaceutical company, has received a Notice of Allowance from the Japan Patent Office for an ExoPTEN patent. The patent covers Extracellular Vesicles (EVs) comprising a phosphatase and tensin homolog (PTEN) inhibitor and their application use. The ExoPTEN drug, currently under development, aims to promote nerve growth and regeneration after acute spinal cord injury. The company has also extended its investor relations agreement with BullVestor Medien GmbH until May 15, 2025.
PartnersInvestment
growth-positive
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
NurExone Biologic Inc., a biopharmaceutical company, has announced the results of its annual general and special meeting of shareholders. The shareholders voted in favor of each resolution put forth at the meeting, including the reappointment of Ziv Haft as the companys auditor, an amendment to the companys equity incentive plan, and a continuance of the company from the Province of Alberta to the Province of Ontario. The company also granted an aggregate of 1,815,900 stock options and 2,000,000 restricted share units to certain officers, directors, employees, and consultants of the company.
Management ChangesInvestment
growth-negative
Is NurExone Biologic (CVE:NRX) In A Good Position To Deliver On Growth Plans?
NurExone Biologic, an unprofitable company, has seen its share price soar by 104% over the last year, attracting investors. However, concerns are raised over the companys cash burn rate. As of March 2024, NurExone Biologic had cash of US$3.3m and no debt, but its cash burn was US$3.9m over the trailing twelve months, giving it a cash runway of roughly 10 months. This indicates that the company must either reduce its annual cash burn or replenish its cash. The companys cash burn increased by 7.9% over the last year, suggesting increased investment in future growth.
Investment
growth-positive
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
NurExone Biologic Inc. has announced its financial and operational results for Q1 2024, highlighting the setup of in-house laboratories and offices, the acceleration of warrants, and a partnership with Vivox Ltd. for preclinical testing. The company also secured approval for listing on the OTCQB Venture Market. The companys CFO, Eran Ovadya, stated that the company maintains a strong cash position and is positioned for sustained growth and continued success. The companys net loss was $0.92 million in Q1 2024, compared to a net loss of $0.70 million in Q1 2023.
InvestmentExpandPartners
growth-positive
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
NurExone Biologic Inc. has announced the appointment of Dr. Ram Petter as a consultant to assist in driving the companys strategic collaborations. Dr. Petter has a distinguished background in the pharmaceutical industry and his addition signals NurExones readiness for industry partnerships and licensing agreements. He will support NurExones operational activities and facilitate the companys strategic engagement. The companys ExoTherapy platform for drug delivery is ready for industry partnerships targeting clinical indications beyond acute spinal cord injury.
Management ChangesPartners
growth-positive
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
NurExone Biologic Inc., a biopharmaceutical company developing therapies for spinal cord injury treatment, has announced that its common shares are now quoted for trading on the OTCQB® Venture Market under the symbol NRXBF. This listing is expected to enhance visibility and facilitate trading by US institutional and retail investors. The company has also received Depository Trust Company (DTC) eligibility for its shares on the OTCQB, which is expected to expand the companys stock reach to a wider audience of potential investors and brokerage firms.
Public TradingExpand
growth-positive
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
NurExone Biologic Inc., a pioneering biopharmaceutical company, has announced that its CEO, Dr. Lior Shaltiel, will present on Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach at the Exosomes of Europe conference in June, 2024. NurExone is developing ExoPTEN, an exosome-loaded nanodrug for patients with acute spinal cord injuries. The conference will bring together experts from academia and industry to discuss advancing exosome products from the clinical stage to commercialization.
Management Changes
growth-positive
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
NurExone Biologic Inc, a biopharmaceutical company, has provided a business update and reported its financial results for Q4 and the financial year ending December 31, 2023. The company received a response from the FDA granting the orphan-drug designation request for treatment of acute Spinal Cord Injury. This is expected to shape the company’s regulatory and go-to-market strategies. The company also commenced the setup of in-house laboratories and offices to bolster its research and development capabilities. NurExone announced its engagement in animal experiments as part of the preclinical testing phase for the submission of an Investigational New Drug application to the FDA.
Investment
growth-positive
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
NurExone Biologic Inc has announced the completion of a combined exercise and expiration of over 12 million common share purchase warrants, resulting in gross proceeds of approximately C$4 million. The funds will be used to boost the companys development and commercial efforts, including the engagement of biopharma collaborators for new indications. The companys CFO, Eran Ovadya, expressed gratitude to the investors for their steadfast confidence in the company and its ExoPTEN drug, which is being developed for patients with acute spinal cord injuries.
Investment
growth-positive
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
NurExone Biologic Inc has announced a strategic service agreement with Vivox Ltd, a leading provider of animal testing services in Israel. The agreement will see Vivox carry out large-scale animal testing as part of NurExones plans to file an Investigational New Drug (IND) application in the US for its ExoPTEN therapy for spinal cord injury. The tests will involve 100 rats and aim to evaluate the optimal dosage of ExoPTEN. The partnership is expected to accelerate the development and regulatory path of ExoPTEN.
Partners
growth-positive
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
NurExone Biologic Inc, a biopharmaceutical company, has announced its intention to expand its market reach by applying for listing on the OTCQB Venture Market in the United States. The company has also applied for DTC eligibility, which will expand its stock reach to a wider audience of potential investors and brokerage firms. The companys chairman, Mr. Yoram Drucker, stated that this move underscores their commitment to enhancing investor engagement and liquidity for their shareholders. NurExone Biologics common shares will continue to trade on the TSX Venture Exchange and on several stock exchanges in Germany.
Public TradingExpand
growth-positive
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
NurExone Biologic Inc., a biopharmaceutical company, has finalized a lease and construction agreement for laboratories and office space on the campus of the Israel Institute of Technology (Technion). The lease period extends until December 31, 2028, with an option to extend for an additional five years. The new facilities will aid in the development of the companys ExoPTEN and ExoTherapy platform. The company has also signed a construction agreement with Biopharmax Group Ltd, a global designer and constructor for leading biotech companies.
ExpandPartners
growth-positive
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
NurExone Biologic Inc., a pioneering biopharmaceutical company, has announced that Dr. Ina Sarel, the Head of CMC, Quality and Regulatory Affairs at NurExone, will be leading a workshop at the upcoming Exosome Characterization & Analytical Development Summit. Dr. Sarel will share insights on the topic of Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product. She will also share the companys development outcomes and regulatory expertise in the field of exosome therapeutics. The summit will take place on April 23-25, 2024 in Boston, MA.
Management ChangesExpand
growth-positive
NurExone’s Intellectual Property Portfolio Expands
NurExone Biologic Inc, a pioneering biopharmaceutical company, is expanding its Intellectual Property (IP) portfolio. The companys IP portfolio describes the ExoTherapy platform’s technology and processes for the production of nanodrugs, including large scale production of exosomes, loading of active molecules, and the composition of the exosomes. The company aims to license the ExoTherapy platform to interested biotech companies. The company also highlighted its innovative bioreactor and biological processes for high yield repeatable production of exosomes. NurExone has an exclusive license from the Technion (Israel Institute of Technology) over a novel patent family.
PartnersExpand
growth-positive
NurExone Launches Licensing Efforts for ExoTherapy Platform
NurExone Biologic Inc., a biopharmaceutical company, has announced its plans to license its proprietary ExoTherapy platform for creating nanodrugs. The platform involves loading therapeutic molecular cargo into exosomes, which have a natural affinity for inflamed tissues, to create a healing environment. The companys first product, ExoPTEN for acute spinal cord injury, has shown promising results in laboratory rats and is expected to be available for human trials in 2025. The company expects success through licensing its technology for other indications.
InvestmentExpand
growth-positive
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
NurExone Biologic Inc. has initiated the Orphan Drug Designation process with the European Medicines Agency (EMA) for its ExoPTEN product, which is being developed for patients with acute spinal cord injury. This follows the recent grant of Orphan Drug Designation by the U.S. Food and Drug Administration (FDA). The Orphan Drug Designation is expected to yield significant market benefits for the company and represents a strategic move to broaden the reach of this promising treatment globally. The company has enlisted the expertise of an external consultant to secure European Orphan Drug Designation.
CustomersPartners
growth-positive
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
NurExone Biologic Inc, a biopharmaceutical company, has announced updates on its partnership with Inteligex Inc, aimed at developing therapies for patients with chronic spinal cord injuries. The collaboration, which combines Inteligexs experience in cell-based therapies and NurExones innovative exosome platform, has been approved for grant funding by the Israel-Canada bilateral Eureka program. Additionally, NurExone has entered into an agreement with bullVestor Medien GmbH to assist with and enhance awareness of the companys products and services in German-speaking countries.
PartnersInvestmentExpand
growth-positive
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has closed a non-brokered private placement. The company issued and sold 7,091,993 units at a price of CAD$0.28 per unit, raising a total of CAD$1,985,758.04. Each unit consists of one common share and one common share purchase warrant. The proceeds from the private placement will be used for working capital purposes. The company plans to use the funds to advance the development of its assets, expand its intellectual property portfolio, and support various corporate purposes.
Investment
growth-positive
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
NurExone Biologic Inc. has unveiled laboratory tests of its secondary two proprietary sequences, marking a significant advancement in the treatment of spinal cord injuries. The company is using its ExoTherapy platform to expand its portfolio of products that will address spinal cord injuries and regeneration of neurons in other CNS indications. The company has developed two selective small inhibiting RNA sequences that target and inhibit proteins within the Peri-Neural Network complex. The companys first product under development, ExoPTEN, has progressed to rat models, with human trials anticipated in the foreseeable future.
InvestmentExpand
growth-positive
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
NurExone Biologic Inc., a pioneering biotechnology company, has announced several updates including receiving Orphan-Drug Designation and completing a Pre-Investigational New Drug meeting with the U.S. FDA for its ExoPTEN drug. The company also received a grant of approximately CAD$350,000 from the Israeli Innovation Authority for a collaboration with Inteligex Inc. to develop a therapy for spinal cord injuries. NurExone has also expanded its Scientific Advisory Board and Advisory Committee, and appointed Eran Ovadya as secretary of the company. The company closed a private placement, raising CAD$1,483,500.70. It plans to submit an IND application for ExoPTEN by Q4 2024 and initiate Phase 1/2 human clinical studies in 2025.
InvestmentManagement ChangesExpand
growth-positive
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
NurExone Biologic Inc., a pioneering biotechnology company, has been granted Orphan-Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for its ExoPTEN therapy. The therapy is a groundbreaking regenerative treatment for acute spinal cord injury. The ODD provides significant benefits to pharmaceutical companies developing drugs for rare diseases, including market exclusivity, financial incentives, regulatory assistance, and support with drug development. The designation is expected to streamline NurExones go-to-market strategy, shorten the regulatory process, save the company millions of dollars, and provide valuable market exclusivity.
InvestmentExpand
Growth-Positive
Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee
NurExone Biologic Inc, a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has welcomed Professor Teodoro Forcht Dagi to its Scientific Advisory Board and Advisory Committee. Despite adversities, the company remains fully operational and continues to prepare for clinical trials and expand to other types of spinal cord injury. The company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.
Management ChangesExpand
growth-positive
NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy
NurExone Biologic Inc, a biopharmaceutical company developing exosome therapy for patients with acute spinal cord injuries, has been awarded a 1M New Israeli Shekels (~CAD$350K) grant by the Israel Innovation Authority. The grant is for a collaboration with Canada-based Inteligex Inc. to develop a hybrid therapy for the complex chronic spinal cord injury market. This partnership combines Inteligex’s expertise in stem cell treatments with NurExone’s ExoTherapy drug delivery platform. The grant is expected to cover a significant part of the Company’s total first year project budget of 2.45M NIS (~CAD$850K).
InvestmentPartners
growth-positive
NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, announced that its CEO, Dr. Lior Shaltiel, will be presenting advances in exosome-based therapy. The presentation will focus on the potential of extracellular vesicles loaded with PTEN-siRNA (ExoPTEN) and the challenges in translating this therapy to the clinical stage. The presentation will take place at the Extracellular Vesicles Forum in Cambridge, UK, on October 10th and 11th. NurExone holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.
Management Changes
growth-positive
NurExone Appoints Dr. Reuter Investor Relations in Europe
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has entered into an investor relations agreement with Dr. Reuter Investor Relations GmbH. The agreement, which begins on September 1, 2023, and runs for a minimum of 6 months, will focus on financial press releases in German-speaking countries. In addition, NurExone has announced the amendment of 12,682,340 common share purchase warrants, which includes a reduction of the exercise price and extension of the expiry date. The amendments aim to optimize the companys capital structure and potentially bolster the companys balance sheet by up to CAD$4.8 million.
PartnersInvestment
growth-positive
The Watchlist by The Market Herald Releases New Interviews with NurExone Biologic and SuperBuzz Discussing Their Latest News
NurExone Biologic and SuperBuzz have been featured in new interviews by The Watchlist by The Market Herald. NurExone Biologic is progressing towards human clinical trials after completing a Pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for its ExoPTEN drug. SuperBuzz, a leader in AI marketing technology, has announced a strategic partnership with a top-tier marketing agency to boost its online marketing and sales initiatives.
PartnersCustomers
growth-positive
NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug
NurExone Biologic Inc has completed a Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the development of ExoPTEN, the companys first ExoTherapy product for patients with traumatic spinal cord injuries. The FDA has provided guidance on the manufacturing and controls of ExoPTEN and agreed that the proposed release testing strategy would be expected to control for safety of the product for use in the planned first-in-human clinical trial. The company plans to submit an IND application for the development of ExoPTEN by Q4, 2024, and expects to initiate Phase 1/2 human clinical studies in 2025.
InvestmentExpand
growth-positive
NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has closed the second and final tranche of its non-brokered private placement. The company issued and sold 750,000 units at a price of CAD$0.275 per unit for aggregate proceeds of CAD$206,250. In total, the company raised CAD$1,483,500.70 from the private placement. The funds will be used for progressing the development activities on the company’s assets, working capital, and for general corporate purposes.
Investment
growth-positive
NurExone Reports Second Quarter 2023 Financial Results and Provides Corporate Update
NurExone Biologic Inc has completed the first tranche of a non-brokered private placement offering of units for gross proceeds of approximately CAD$1.3 million. The funds are expected to extend the companys cash runway into 2024. The company has also strengthened its Board of Directors with the appointment of Dr. Gadi Riesenfeld, former President of Pharmos Corporation. NurExone has reported positive imaging results from an internal preclinical study of its investigational drug ExoPTEN, which confirmed successful nerve regeneration following traumatic transection of the spinal cord in rats. The company has also announced a collaboration with Particle Metrix.
InvestmentManagement Changes
growth-positive
NurExone Announces Private Placement
NurExone Biologic Inc. announces its intention to complete a non-brokered private placement of a minimum of 2,727,272 units and a maximum of 5,090,909 units at a price of CAD$0.275 per unit. The minimum gross proceeds are expected to be $750,000 and maximum gross proceeds of $1,400,000. The company intends to use the proceeds for working capital purposes. The private placement is subject to the approval of the TSX Venture Exchange.
Investment
growth-positive
NurExone Biologic Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery
NurExone Biologic Inc. has announced significant advancements in extracellular vesicles (EVs) functionality. The company has achieved enhanced EV functionality through its proprietary and patented 3D-Flow production. This includes an amplified immuno-modulatory response and improved cellular uptake. The company aims to unlock the full potential of EVs as powerful therapeutic tools. The companys wholly-owned subsidiary, NurExone Biologic Ltd. has obtained an exclusive worldwide license from the Technion to develop and commercialize the production process for use for additional indications. The company is pursuing a patent application in the United States and other key markets.
InvestmentPartnersExpand
growth-positive
NurExone Announces Appointment of New Director and Provides Corporate Updates
NurExone Biologic Inc. has announced the appointment of Dr. Gadi Riesenfeld to its board of directors, replacing Mr. Ron Mayron. The company also held its annual and special meeting of shareholders on June 28, 2023, where all proposed resolutions were approved, including the adoption of the companys omnibus equity incentive plan. Furthermore, the company plans to apply to the TSX Venture Exchange to amend the exercise price of 13,815,730 outstanding common share purchase warrants. A patent covering NurExones ExoPTEN technology has also been recently approved by the Russian Patent Office.
Management Changes
growth-positive
Regeneration and Reinnervation of Spinal Cord in Rats Treated with NurExone's Intranasal ExoPTEN
NurExone Biologic Inc. has reported positive imaging results from a preclinical study of its drug ExoPTEN, which showed successful nerve regeneration in rats with spinal cord injuries. The study demonstrated that 75% of the rats regained hind limb reflex, motor function, and sensory control after treatment with ExoPTEN. Diffusion Tensor Imaging (DTI) confirmed the structural integrity of the spinal cord in the treated rats. ExoPTEN is being developed as a minimally invasive therapy for spinal cord injuries, administered intranasally. The company aims to translate these results to human patients. NurExone Biologic Inc. is a pharmaceutical company listed on the TSX Venture Exchange.
Investment
growth-positive
Regeneration and Reinnervation of Spinal Cord in Rats Treated with NurExone's Intranasal ExoPTEN
NurExone Biologic Inc. has reported positive imaging results from an internal preclinical study of its investigational drug ExoPTEN. The study showed successful nerve regeneration following traumatic transection of the spinal cord in rats. The companys ExoPTEN drug caused 75% of rats to regain hind limb reflex, some motor function, and sensory control. The results align with previous results showing a remarkable recovery of motor function in 75% of paralyzed rats suffering from spinal cord injuries and treated with the new therapy. The company is eager to advance its research and clinical trials to translate these results to human patients.
InvestmentExpand
growth-positive
NurExone and Particle Metrix Announce Collaboration in Extracellular Vesicles Analysis Using State-of-the-art Analytic Device
NurExone Biologic Inc, a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has announced a collaboration with German company, Particle Metrix. The partnership will see NurExone use a Nanoparticle Tracking Analysis instrument from Particle Metrix to validate their methodology for analysing loaded exosomes for their ExoPTEN drug. The collaboration will also allow NurExone to offer analytic services to other companies developing exosome-based therapies. The ExoPTEN drug is targeted at the $2.9 billion global market for patients with acute spinal cord injury.
PartnersExpand
growth-positive
NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update
NurExone Biologic Inc, a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has released its financial results for Q1 2023. The company has been achieving key milestones for its investigational ExoPTEN drug and is developing an exosome therapy platform for the medical industry. The company has expanded its intellectual property portfolio and disclosed promising pre-clinical study results. The company aims to advance its strategy of commercializing its ExoPTEN drug product, establishing a platform for ExoTherapy production and expanding its overall business.
CustomersPartnersInvestmentAcquired-byAcquisitionPublic TradingManagement ChangesLayoffsExpand
growth-positive
NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN, Designed for Treating Acute Spinal Cord Injuries
NurExone Biologic Inc. has received a patent from the United States Patent and Trademark Office for its Exo-PTEN technology, which is used in the development of biologically-guided exosome therapy for patients with traumatic spinal cord injuries. The patent protects NurExones drug composition and methods for non-invasive intranasal administration of exosome-based treatment. The company plans to file a continuation patent application to further expand its intellectual property portfolio. The grant of this patent is a significant milestone for NurExone and strengthens its position in the field of Central Nervous System and neurological diseases treatment.
Partners
growth-positive
NurExone Engages Investor Relations Service Provider
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has engaged Litchfield Hills Research, LLC to perform investor relations services. The agreement will cost NurExone an annual cash fee of USD$14,000, with USD$5,000 payable upon entering into the agreement. The remaining amount will be payable in three equal installments over the following nine months. Litchfield will publish equity research on NurExone on 15 global financial platforms and target its research to institutional investors.
Partners
growth-positive
NurExone Announces Equity Incentive Plan Grants and Director Resignation
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has granted an aggregate of 1,145,520 incentive stock options and 1,275,000 restricted share units under the companys equity incentive plan to certain officers and directors. The options are exercisable for one common share of the company at a price of $0.28 per common share. The company also announced the resignation of Eyal Flom from the board of directors for personal reasons.
Management Changes
Growth-Negative
NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has released its financial results for 2022. The companys R&D investment grew by 143.9% from $0.57 million in 2021 to $1.39 million in 2022 due to increased preclinical trials. However, the company recorded losses of $8.17 million, a 396.0% increase over 2021, due to increased investment in R&D and the reverse takeover transaction related cost. The company also announced interim results of an internal pre-clinical study of its proprietary ExoPTEN drug, demonstrating significant improvement in rats with spinal cord injuries.
InvestmentPublic TradingManagement Changes
growth-positive
NurExone Biologic Reports Additional Positive Preclinical Trial Outcomes with ExoPTEN: 75% of Paralyzed Rats Show Recovery after Acute Spinal Cord Injury Study
Biopharmaceutical firm NurExone Biologic Inc. has disclosed positive results from a preclinical study of its investigational drug ExoPTEN for spinal cord injuries. The study showed that 75% of paralyzed rats treated with ExoPTEN regained hind limb reflex, motor function, and sensory control without self-harm. ExoPTEN is being developed as a minimally invasive ExoTherapy for spinal cord injuries. The results of the study will be presented at a scientific meeting. The global market for spinal cord injury treatment is projected to reach $5.2 billion by 2027. NurExone Biologic Inc. is a pharmaceutical company listed on the TSX Venture Exchange.
CustomersInvestment
growth-positive
NurExone Biologic Reports Additional Positive Preclinical Trial Outcomes with ExoPTEN: 75% of Paralyzed Rats Show Recovery after Acute Spinal Cord Injury Study
Biopharmaceutical firm NurExone Biologic Inc. has disclosed additional results from an internal preclinical study of its investigational drug ExoPTEN. The drug, developed using NurExone’s proprietary ExoTherapy platform, has shown effective treatment in 75% of paralyzed rats suffering from spinal cord injuries. The drug is being developed to be a minimally invasive ExoTherapy for spinal cord injuries, yielding neuron regeneration and rewiring in traumatically damaged spinal cords. The projected global market of the industry is $5.2 billion by 2027, with $2.9 billion for acute spinal cord injury and $2.3 billion for Exosome-based technology.
InvestmentExpand
growth-positive
NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has announced the interim results of a preclinical study of its ExoPTEN drug. The study was designed to assess the impact of ExoPTEN on the motor, reflex, and sensory recovery of rats, following full transection of the spinal cord. The interim results showed that 75% of the rats responded to treatment and recovered hind limb reflex, rehabilitated some motor function, and recovered sensory control. The company aims to capitalize on the $2.9 billion market for acute Spinal Cord Injuries.
Investment
growth-positive
NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug
NurExone Biologic Inc., a biopharmaceutical company, has announced the interim results of its internal preclinical study on its ExoPTEN drug. The study showed that ExoPTEN demonstrated motor, reflex, and sensory improvement in rats with complete spinal cord severing. The results suggest that ExoPTEN can partially rewire the spinal cord and bring about recovered capability. ExoPTEN is based on NurExones proprietary ExoTherapy platform, which uses exosomes loaded with therapeutic molecules to promote neuron regeneration and rewiring in traumatically damaged spinal cords. The interim results will be presented at the ILANIT Experimental Biology Conference 2023. NurExone Biologic Inc. is developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
CustomersInvestment
growth-positive
NurExone Biologic Inc. Emerges as a Promising Investment Opportunity in Biotechnology
NurExone Biologic Inc, a Toronto-listed biopharmaceutical company, is developing ExoPTEN, a platform for producing and loading exosomes with pharmaceutical cargo targeting spinal cord injuries. The companys flagship product, ExoPTEN, is being developed to be a minimally invasive therapy for spinal cord injuries, yielding neuron regeneration and rewiring in traumatically damaged spinal cords. NurExone recently received a notice of allowance from the United States Patent and Trademark Office for its ExoPTEN technology. The global market for such technology is projected to reach $5.2 billion by 2027. The companys management team is composed of experienced professionals in the pharmaceutical industry.
InvestmentCustomersPartners
growth-positive
Israeli biotech startup developing innovative platform for treatment of
Israel-based biotech startup NurExone Biologic is developing a revolutionary biological Extracellular Vesicles (EVs)-based technology drug platform to provide functional recovery from damage in the central nervous system (CNS). The company is developing treatment for full or partial reversal of paralysis and improving the lives of patients following spinal cord injury using bio-guided exosomes loaded with modified small interfering RNA (siRNA) sequences. NurExones technology is being used to develop treatment of various conditions, including spinal cord injury (SCI), traumatic brain injury, and other CNS indications. The article highlights the potential of NurExones technology and its impact on the biotech industry in Israel.
InvestmentPartners
growth-positive
United States Patent Office Allows Patent to Exosome Biomedical Company Nurexone
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has received a notice of allowance from the United States Patent and Trademark Office for its Exo-PTEN technology. The patent covers the drug composition and methods for non-invasive intranasal administration of exosome-based treatment. The company plans to file additional patent applications to further strengthen its intellectual property portfolio. The patent was submitted by the Technion-Israel Institute of Technology and Ramot, a Tel Aviv Universitys technology transfer company.
CustomersPartnersManagement Changes
growth-positive
NurExone Issues Annual Shareholder Letter
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has announced significant achievements in 2022. The company completed its public listing in Canada on the TSX Venture Exchange and began trading under the ticker symbol NRX in June 2022. NurExone is also pursuing healthcare regulatory approval from the U.S. Food and Drug Administration (FDA). The company has established strategic collaborations and partnerships with Yissum Research Development Company, denovoMATRIX GmbH, and Nanometrix Ltd. NurExone also plans to commercialize its technology portfolio by licensing it to other organizations within the global biopharmaceutical industry.
CustomersPartnersPublic TradingManagement ChangesExpand
growth-positive
NurExone Announces Completion of Securites for Debt Settlement
NurExone Biologic Inc., a biopharmaceutical company, has announced the completion of its securities for debt settlement on December 6, 2022. The company agreed to settle debts amounting to CAD$46,523.69 by issuing 122,430 common shares at the market price of CAD$0.38 per share. This follows a recent Reverse Takeover Transaction after which NurExone began trading under the new name NurExone Biologic Inc. with the trading symbol NRX. The company is developing a platform for biologically-guided ExoTherapy for patients with traumatic spinal cord injuries.
Investment
growth-positive
Update: NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
NurExone Biologic Inc., a biopharmaceutical company, has reported successful results from a pre-clinical loading efficiency study of its proprietary loading technology for producing exosome-based therapies. The study indicated that NurExones loading technology does not compromise the functionality of the siRNA to knock down gene expression and achieved the desired loading efficiency. The company plans to monetize its proprietary technology platform and explore potential licensing opportunities for this loading technique. NurExones exosome-based therapy is intended for patients with traumatic spinal cord injuries.
InvestmentExpand
growth-positive
NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has reported successful results from a pre-clinical loading efficiency study. The study showed that NurExones proprietary loading technology could serve as an efficient process for loading therapeutic molecular cargo into exosomes. The companys platform for exosome-based therapy production is planned to include large-scale exosome production, therapeutic cargo, and a unique technology to load the therapeutic cargo. NurExone intends to monetize its proprietary technology platform and will explore potential licensing opportunities for this loading technique once it is finalized.
InvestmentExpand
growth-positive
NurExone Announces Securities for Debt Settlement
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spine injuries, has announced that it will settle debts amounting to CAD$46,523.69 by issuing 122,430 common shares at a deemed price of CAD$0.38 per share. These debts were incurred prior to the recent Reverse Takeover Transaction, after which NurExone began trading under its new name. The common shares will be issued upon acceptance by the TSX Venture Exchange and will be subject to a four-month plus one-day hold period.
Public Trading
growth-positive
NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spinal cord injuries, has released a corporate update and reported financial results for Q3 2022. The company is working towards obtaining U.S. FDA approval for its drug platform and is also advancing other areas of its business, including securing more international collaborations with biotechnology companies. NurExone has also settled EnerSpar Corp.s debts that were incurred prior to its go-public listing. The company has signed partnerships with Yissum Research Development Company, denovoMATRIX GmbH, and Nanometrix Ltd.
PartnersInvestment
growth-positive
NurExone Announces Completion of Securities for Debt Settlements
NurExone Biologic Inc., a biopharmaceutical company developing exosome therapy for patients with traumatic spine injuries, has announced the completion of its securities for debt settlements. The company settled debts amounting to CAD$136,155.83 by issuing 170,195 common shares at a deemed price of CAD$0.80 per share. Additional debts amounting to CAD$75,000 were settled with the issuance of 178,571 common shares at a deemed price of CAD$0.42 per share. The shares will be subject to a four-month plus one-day hold period as per the policies of the TSX Venture Exchange.
Investment
growth-positive
Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries
Medigus Ltd announced that Polyrizon Ltd, in which Medigus owns a stake, has signed a binding Collaboration Agreement with NurExone Biologic Inc. Under the agreement, Polyrizon will use its advanced Trap and Target™ platform to develop an intranasal delivery system for NurExones ExoTherapy for patients with traumatic spinal cord injuries. NurExone will cover the costs of formulation development and pay development fees to Polyrizon. The collaboration may also involve regulatory submissions and royalties based on product sales. The manufacturing and marketing rights for the formulations are exclusive to NurExone. The agreement is expected to have a positive impact on Medigus Ltds growth.
PartnersInvestment
growth-positive
NurExone Biologic Inc. Opens the Market
NurExone Biologic Inc. celebrates its listing on TSX Venture Exchange. The company is developing a biological extracellular vesicles-based technology drug platform for reversing paralysis and improving the quality of life of patients with spinal cord injury.
Public Trading
Employee Info
| Employees (range) | 11-50 |
| Exact count | 26 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 7 classification IDs that could be used for matching.
NurExone Biologic Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516209202 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-06-28T00:00:00.000Z |
| Created | 2023-06-28T00:00:00.000Z |
| Status detail | Public on TSXV on Jul, 2022; |